

Q4 FY25 Quarterly Activity Report

Highlights:

- **Q4 FY25 cash receipts of \$2.1m**, leading to **positive operating cash inflow of \$0.3m**
- **Q4 FY25 revenue (unaudited) of \$2.0m** (19% recurring), up **148%** on Q3 FY25, **+14%** pcp
- **Annual Recurring Revenue (ARR) of \$1.9m** at the end of Q4 FY25 (**up 14%** on Q3 FY25, **+49%** pcp)
- **Key contracts secured during Q4 FY25, notably:**
 - **Amplar Health** (15-month phased rollout across up to 30 sites with a TCV of ~\$1.0m; ~\$0.7m upfront hardware and \$0.14m ARR)
 - **A leading ASX mining company** (roll out across 13 medical centres and one aircraft with a TCV of ~\$0.4m; ~\$0.3m upfront hardware and \$0.1m ARR)
 - **Central & Eastern Sydney PHN (CESPHN)** expanded implementation to 10 further facilities (\$0.2m)
 - **Healthy North Coast PHN (HNCPHN)** expanded implementation to 7 further facilities (\$0.2m)
- **Increasing referenceability across core verticals** with multiple pilot programs and enterprise discussions progressing to contract stage

Visionflex Group Limited (“**VFX**” or the “**Company**”), a leader in virtual healthcare technology, is pleased to issue its Appendix 4C and quarterly market update for the 3 months ending 30 June 2025.

Visionflex CEO & Managing Director, Joshua Munday said: “Our Q4 performance reflects the strength of our underlying business and the continued execution of our strategy. We achieved strong commercial outcomes, successfully converting a maturing pipeline into new revenue, securing key strategic wins and momentum with subscription renewals.”

Financial Performance

Customer cash receipts totaled \$2.1m in Q4 FY25, a 136% increase on the receipts collected in Q3 FY25, reflecting improved customer conversion, growing commercial momentum and typical seasonality in contract execution and customer billing cycles.

Driven by strong cash receipts, the Company delivered positive operating cash flows of \$0.3m for Q4 FY25, representing a significant improvement from the \$0.9m operating cash outflow in Q3 FY25 (excluding \$0.4m interest costs paid in Q3 FY25).

Operating and administration payments for the quarter remained consistent with Q2 and Q3 at \$1.8m, as the Company continues to exercise cost discipline and operational efficiencies while also maintaining sufficient resourcing to support future growth.

As at 30 June 2025, the Company has \$1.9m of cash with a further \$1.5m available if required under its existing \$4.0m debt facilities with cornerstone investors John Plummer and Adcock Private Equity.

Unaudited Q4 FY25 revenue was \$2.0m, up 148% on Q3 FY25 and 14% on the prior corresponding period (pcp). Approximately 19% of Q4 FY25 revenue was recurring, aligned with the Company's focus on growing a more predictable, high-margin revenue base.

ARR increased by 14% during the quarter to reach \$1.9m, a 49% increase compared to Q4 FY24. This growth reflects both ARR from new customer wins and successful expansion within the existing customer base, including upgrades and renewals across key market segments.

As agreed by the Board in March 2025, and in recognition of the aligned interests, no Director fees were paid in Q4 FY25. It is planned that Director fees will resume in FY26. Remuneration for Mr Munday and Mr Kafrouni in their executive roles for Q4 FY25, has been disclosed as related party transactions in the Appendix 4C.

Operating Performance

During Q4 FY25 the following significant sale agreements were signed:

- **Ampliar Health** was successful in securing a transformative Australian government funded virtual nursing pilot across up to 30 residential aged care facilities (RACF's) and selected Visionflex as its technology partner. The 15-month phased rollout of Visionflex's solution, carries a total contract value of ~\$1.0m, split into ~\$0.7m of upfront hardware sales and \$0.14m of ARR upon full deployment. Australia is home to >2,600 RACFs¹, providing care for 190,000 permanent residents².
- **A leading ASX mining company** committed to implementing Visionflex's advanced telehealth solution across 13 medical centres and one Helicopter Emergency Medical Service aircraft to deliver enhanced access to medical services, streamlined operations, and improved safety for their workforce. The initial first-year total contract value is \$0.4m, split into ~\$0.3m of upfront hardware sales and \$0.1m of ARR.
- **Central and Eastern Sydney PHN** - expanded to a further 10 additional facilities, (contract worth \$0.2m), taking Visionflex technology deployed sites to 52. With 150 Residential Aged Care Facilities (RACFs)³ across the CESPHN footprint, this represents ~35% regional penetration to date.
- **Healthy North Coast PHN** - expanded to a further 7 additional facilities, (contract worth \$0.2m), taking Visionflex technology deployed sites to 18. With 78 RACFs⁴ across the HNC PHN footprint, this represents ~23% regional penetration to date.

Outlook

Visionflex enters FY26 with a solid foundation, underpinned by ARR of \$1.9m. The increasing adoption and referenceability of Visionflex's solutions across multiple key customer verticals continues to drive confidence in the conversion of multiple active trial sites into large-scale, multi-site contracts.

Building on the momentum achieved in Q4 FY25, Visionflex is set to launch a new solution tailored specifically for the In-Home Care market in Q1 FY26. With over 900 providers delivering home care through 2,300+ services nationally⁵, this represents a significant new addressable market opportunity. The Company is well-positioned to capitalise on this market segment by leveraging its proven technology, sector experience, and scalable deployment model to support sustainable long-term growth.

The Company remains focused on maintaining this positive trajectory as it enters FY26, with an emphasis on scaling sustainably and building further shareholder value.

-- END --

This announcement was approved for release by the Board of Directors.

¹ <https://www.gen-agedcaredata.gov.au/topics/providers.-services-and-places-in-aged-care>

² <https://www.australianageingagenda.com.au/noticeboard/resources/report-shows-aged-care-trends/>

³ https://cesphn.org.au/wp-content/uploads/2022/05/CESPHN_Submission_to_Royal_Commission_into_Aged_Care_Quality_and_Safety_14.7.2019_Final2.pdf

⁴ <https://hnc.org.au/wp-content/uploads/2025/01/HealthyNorth-Coast-PHN-Health-Needs-Assessment-2024-2026.pdf>

⁵ <https://www.gen-agedcaredata.gov.au/topics/providers.-services-and-places-in-aged-care>

For more information:

Joshua Munday
Managing Director and CEO, Visionflex Group
jmunday@visionflex.com

About Visionflex Group

At Visionflex, we believe that healthcare should be accessible, efficient, and connected. Our integrated hardware and software platform allows healthcare providers to deliver comprehensive, collaborative care in real time, no matter the location. From metropolitan health networks to community-based care, Visionflex is reshaping how healthcare is delivered by connecting healthcare teams with the tools and technology needed to provide effective, efficient, and high-quality care. For more information, visit vfx-group.com.

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Visionflex Group Limited

ABN

25 138 897 533

Quarter ended ("current quarter")

30 June 2025

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	2,074	4,543
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(547)	(1,806)
	(c) advertising and marketing	(31)	(161)
	(d) leased assets	(39)	(153)
	(e) staff costs – Redundancy costs	-	-
	(e) staff costs – Wages	(817)	(4,057)
	(f) administration and corporate costs	(331)	(1,543)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	-	(467)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	480
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	309	(3,164)
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(1)	(29)
	(d) investments	-	-
	(e) intellectual property	(1)	(1)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(2)	(30)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	2,854
3.2	Proceeds from issue of convertible debt securities	500	1,500
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(2)	(432)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other	-	-
3.10	Net cash from / (used in) financing activities	498	3,922

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,084	1,161
4.2	Net cash from / (used in) operating activities (item 1.9 above)	309	(3,164)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2)	(30)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	498	3,922
4.5	Effect of movement in exchange rates on cash held	1	1
4.6	Cash and cash equivalents at end of period	1,890	1,890

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,890	1,084
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,890	1,084

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount for payments to related parties and their associates included in item 1	162
6.2	Aggregate amount for payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	4,000	2,460
7.3	Other (please specify)	-	-
7.4	Total financing facilities	4,000	2,460
7.5	Unused financing facilities available at quarter end		1,540
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	<p><u>Key terms of the Standby Convertible note facility</u></p> <p>The credit standby arrangements relate to:</p> <ol style="list-style-type: none"> 1) A \$2.5 million convertible note facility with a cornerstone shareholder investor, John Plummer. This convertible note facility was previously \$5.2 million (from October 2022 and earlier periods). In February 2025, key terms of this facility were varied with the facility limit reduced to \$2.5 million and the availability period extended to 28 February 2026. As at 30 June 2025, \$1.96 million had been drawn down under the facility, of which \$0.96 million was due for repayment or conversion by 28 February 2026, \$0.5 million was due for repayment or conversion by 16 December 2026 and \$0.5 million was due for repayment or conversion by 26 May 2027. As at 30 June 2025, \$0.54 million was available to draw down under this facility. 2) A \$1.5 million convertible note facility issued to Adcock Private Equity. This convertible note facility was previously \$3.2 million (from February 2023). In February 2025, key terms of this facility were varied with the facility limit reduced to \$1.5 million and the availability period was extended to 28 February 2026. As at 30 June 2025, \$0.5 million had been drawn down under the facility and was due for repayment or conversion by October/November 2026. As at 30 June 2025, \$1.0 million was available to draw down under this facility. <p>The key terms of both facilities include:</p> <ul style="list-style-type: none"> • The convertible note with each investor is repayable 24 months from the date of each drawdown. Repayments of amounts drawn prior to July 2024 have been extended until at least 28 February 2026; • Line fee of 1% per annum; • Interest rate of the Reserve Bank of Australia cash rate (3.85%) as at 30 June 2025 plus 7.5% per annum, therefore 11.35% per annum as at 30 June 2025, payable quarterly in arrears unless otherwise agreed in writing between the Company and each investor; • The facility agreement includes a provision to renegotiate interest rate further downwards subject to the Group delivering three consecutive cash flow positive quarters; • Usual covenants for a facility of this nature and scope including: unsecured obligation, no debt subordination without consent, anti-dilution provisions; • The Facility can be repaid in part or in full or reduced at any time at the election of the Group; • The facilities constitute unsecured debt obligations of the Company; and • Provisions allowing for conversion into shares of a portion of the existing debt. 		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	309
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,890
8.3	Unused finance facilities available at quarter end (item 7.5)	1,540
8.4	Total available funding (item 8.2 + item 8.3)	3,739
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<p><i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i></p>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: Not applicable	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: Not applicable	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: Not applicable	
<p><i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i></p>		

Compliance statement

1. This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
2. This statement gives a true and fair view of the matters disclosed.

Date: 17 July 2025

Authorised by: The Board of Visionflex Group Limited
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: *Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

Q4 FY25 Results Presentation

Visionflex Group Ltd (ASX:VFX) (“**VFX**” or the “**Company**”), a leader in virtual healthcare technology, is pleased to announce that it is holding an investor webinar today which will follow the release of the Q4 FY25 financial results this morning.

Webinar Details: 12pm AEST, Thursday 17 July 2025.

Link to register to attend the presentation: <https://zoom.us/meeting/register/AS8y0bi5Q9moRbq67psmQQ>

A copy of the presentation is attached to this announcement and a replay of the webinar will be available at the above mentioned link shortly following the conclusion of the live session.

-- END --

This announcement was approved for release by the Board of Directors.

For more information:

Joshua Munday
Managing Director and CEO, Visionflex Group
jmunday@visionflex.com

About Visionflex Group

At Visionflex, we believe that healthcare should be accessible, efficient, and connected. Our integrated hardware and software platform allows healthcare providers to deliver comprehensive, collaborative care in real time, no matter the location. From metropolitan health networks to community-based care, Visionflex is reshaping how healthcare is delivered by connecting healthcare teams with the tools and technology needed to provide effective, efficient, and high-quality care.

For more information, visit vfx-group.com

Visionflex Group

ASX:VFX


Q4 FY25 Results

17 JULY 2025




The Visionflex mission

For personal use only Empowering health practitioners globally with cutting edge technologies to elevate patient outcomes.



Visionflex Group



Visionflex proprietary hardware and software connect a range of third-party medical devices to empower practitioners to deliver world class virtual care.

Q4 FY25 Highlights



\$2.0M Revenue

~19% from recurring software & support
148% up on Q3 FY25 and 14% on pcip



\$1.9M ARR*

Up 14% from Q3 FY25 and 49% on pcip



\$2.1M Cash Receipts

Up 136% from Q3 FY25 and 2% down on pcip



\$0.3M Operating Cash Inflow

Compared with \$0.9M cash outflow
(excluding \$0.4m interest payments) in Q3
FY25



Several Key Contracts Secured

Amplar Health partnership, leading ASX
mining company, Central & Eastern Sydney
PHN expansion, Healthy North Coast PHN
expansion



\$1.9M Cash Balance


Additional debt headroom available of \$1.5m

(*) Annual Recurring Revenue (ARR) is recognised as revenue over the contracted period.

Q4 FY25 Financial Trends


For personal use only

REVENUE (\$m)



- Q4 FY25 revenue of **\$2.0m**, with **~19%** from recurring software & support.
- 148% up on Q3 FY25 and 14% on pcip


ARR (\$m)



- Contracted ARR of **\$1.9m**, **up 14%** from Q3 FY25 and 49% on the pcip.
- \$0.4m contracted ARR sold in Q4 FY25.


Q4 FY25 Financial Trends cont.

CASH RECEIPTS (\$m)



- Q4 FY25 cash receipts of **\$2.1m** up 136% from Q3 FY25 and 2% down on pcp


NET OPERATING CASH FLOW (\$m)



- Q4 FY25 net operating cash inflow of **\$0.3m** compared with \$0.9M cash outflow (excluding \$0.4m interest payments) in Q3 FY25

Q4 FY25 Financial Trends cont.

For personal use only



- Net cash position is defined as total cash less borrowings from DFA holders.

Business Update

Key contracts secured during Q4 FY25 included:



Amplar Health (Aus), the health services division of Medibank

- Deploy VFX solution in a transformative Aust gov't funded virtual nursing pilot across up to 30 residential aged care sites facilities.
- 15-month phased rollout with TCV of ~\$1.0m, split into ~\$0.7m of upfront hardware sales & \$0.14m of ARR upon full roll-out.



A leading ASX mining company

- Deploy VFX solution across 13 medical centres and one Helicopter Emergency Medical Service aircraft to deliver enhanced access to medical services.
- TCV of ~\$0.4m, split into ~\$0.3m of upfront hardware sales & \$0.1m of ARR upon full roll-out.

Business Update cont.

Key contracts secured during Q4 FY25 included:



Central and Eastern Sydney PHN

- Expanded to 10 additional facilities and added peripherals (combined \$0.2m), taking Visionflex technology deployed sites to 52.



Healthy North Coast PHN

- Expanded to 7 additional facilities and added peripherals (combined \$0.2m), taking Visionflex technology deployed sites to 18.

Outlook – Q4 FY25 & Beyond

For personal use only



Strategic plan to deliver profitable growth

- Positive momentum – operating cashflow positive (\$0.3m) in Q4 FY25.
- Targeted growth verticals – key industry verticals: aged care, home care, Indigenous health, and resources.
- Quality revenue – Continued emphasis on high-margin, recurring revenue streams.
- Scalable growth – Leveraging strategic partnerships and international opportunities.



Transitioning to recurring revenue via SaaS

- Transition to SaaS pricing delivering growth in annual recurring revenue (ARR) with 49% growth on the pcip.
- ARR of \$1.9m as of 30 June 2025.

Outlook – Q4 FY25 & Beyond cont.

For personal use only



Expanding pipeline of customers

- Multiple government funded customers across Primary Health Networks and Local Health Districts.
- Growth in other key industry verticals including:
 - aged/home care;
 - regional primary care;
 - indigenous health;
 - resources sector.



Product Innovation

- New market-ready solution – Launch software tailored for the In-Home Care sector, targeting the 900+ providers delivering home care through 2,300+ services nationally.
- Enhanced interoperability – Strengthening third-party integrations to streamline clinical workflows.
- Customer-led development – Prioritising features driven by feedback from aged care and Indigenous health providers.

For personal use only

Important notices

This results presentation (Presentation) has been prepared by Visionflex Group Limited ACN 138 897 533 (ASX:VFX) (**Company**) and is dated 17 July 2025.

Acceptance

The information in this Presentation remains subject to change without notice. By accepting this Presentation, you agree to be bound by the following limitations and conditions.

Summary information

This Presentation contains summary information about the Company, its subsidiaries and their activities which is current as at the date of this Presentation (unless otherwise noted) and the information in this Presentation remains subject to change without notice. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the *Corporations Act 2001 (Cth)* or the securities laws of any other jurisdiction.

This Presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged on the Australian Securities Exchange (ASX) which are available at www.asx.com.au or www.visionflex.com.au

Not an offer

This Presentation is not a prospectus, product disclosure document or other offering document in relation to securities under Australian law. It has not been and will not be filed with or approved by any regulatory authority in Australia, including the Australian Securities and Investments Commission (ASIC), or any other jurisdiction. This Presentation does not constitute and should not be considered as an offer, invitation or recommendation to subscribe for or purchase any security in the Company in any jurisdiction. The distribution of this document in jurisdictions outside Australia may be restricted by law. If you are outside Australia, you may not be a person to whom an offer of securities in the Company may lawfully be made under the applicable laws in the jurisdiction in which you are situated without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. Any such restrictions should be observed.

Not investment advice

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire any securities in the Company. Neither this Presentation nor anything contained in it forms the basis of any contract or commitment and no agreement to subscribe for securities will be entered into on the basis of this Presentation. This Presentation does not take into account any recipient's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in the Company is considered speculative in nature and is subject to known and unknown risks, some of which are beyond the control of the Company. Before making any investment decision in connection with the acquisition of securities in the Company, investors should consult their own legal, tax, and/or financial advisers in relation to the information in, and action taken on the basis of, this Presentation and the Company more generally. The Company does not guarantee any particular rate of return or the performance of the Company, or the repayment of capital and nor does it guarantee any particular tax treatment.

Financial information

The historical financial information in this Presentation is, or is based upon, information that has been lodged with the Australian Securities Exchange (ASX). This Presentation should be read in conjunction with the Company's 3Q FY24 4C Appendix and its accompanying notes.

In this Presentation, all dollar values are in Australian dollars (A\$), unless otherwise stated.

A number of figures, amounts, percentages, estimates, calculations of values and fractions in this Presentation are subject to the effect of rounding. Accordingly, the actual calculations of these figures may differ from the figures set out in this Presentation.

Past performance

Statements about past performance in this presentation is given for illustrative purposes only and cannot be relied upon as an indicator of, and provides no guidance as to, future performance of the Company.

Forward-looking statements

This Presentation may contain certain forward-looking statements and comments about future events, including the outcome and effects. Forward-looking statements can generally be identified by the use of words such as 'project', 'foresee', 'plan', 'expect', 'aim', 'intend', 'anticipate', 'believe', 'estimate', 'may', 'should', 'will' or similar expressions. Forward-looking statements involve known and unknown risks, significant uncertainties, assumptions, contingencies, and other factors, many of which are outside the control of the Company, are subject to change without notice, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and which may cause the actual results or performance of the Company to be materially different from any results or performance expressed or implied by such forward-looking statements. Such forward-looking statements speak only as of the date of this Presentation. Forward looking statements should not be relied on as an indication or guarantee of future performance.

No representation, warranty or undertaking is made that any projection, forecast, assumption or estimate contained in this Presentation should or will be achieved. Recipients of this Presentation must conduct their own independent investigation, evaluation and analysis of the matters and data set out in this Presentation and other publicly available information about the Company, and rely entirely on such investigation and analysis.

Disclaimer

To the maximum extent permitted by law, no representation, warranty or undertaking (express or implied) is made, and no responsibility is accepted by the Company or any of its affiliates, related bodies corporate, partners, shareholders, directors, officers, employees, representatives, consultants or advisers or any other person (Parties) as to the adequacy, accuracy, completeness or reasonableness of any statement or any of the information contained in or referred to in this Presentation or as to any other related matter. To the maximum extent permitted by law, none of the Parties takes any responsibility for any loss, damage or cost suffered as a result of any inadequacy, incompleteness or inaccuracy in any such statement or information.

Except as required by law or regulation (including the ASX Listing Rules), the Company does not undertake to provide any additional or updated information, whether as a result of new information, future events, results or otherwise, in relation to any information in this Presentation, including any forward-looking statement.

To the maximum extent permitted by law, the Parties do not accept any liability to any person for any direct, indirect or consequential loss, damage or cost arising from the use of this material. This Presentation is not a recommendation by any of the Parties that any recipient invest in the Company.

Photographs and Diagrams

Photographs used in this Presentation which do not have descriptions are for illustration only and should not be interpreted to mean that any person shown endorses this Presentation or its contents or that the assets shown in them are owned by the Company. The photographs contained in this Presentation are the property of or are licensed to the Company and are protected under copyright laws. No permission is granted for the reproduction of these photographs outside of their appearance in this Presentation. Diagrams in this Presentation have been prepared by the Company and are illustrative only and may not be drawn to scale. Unless otherwise stated, all data contained in charts, graphs and tables is based on information available at the date of this Presentation.

For personal use only

Visionflex Group

Visionflex Group Limited
Unit 1, 8 Prosperity Parade,
Warriewood NSW 2102

VFX-GROUP.COM

Joshua Munday
MANAGING DIRECTOR
& CHIEF EXECUTIVE OFFICER
E: jmunday@visionflex.com

